These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38457926)

  • 1. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
    Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
    Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
    Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
    Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
    Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
    Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRF4 addiction in multiple myeloma.
    Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
    Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
    Ikeda S; Tagawa H
    Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.
    Zhang C; Gao C; Xu Y; Zhang Z
    Gene; 2014 Aug; 546(1):73-9. PubMed ID: 24835310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRF4 is a suppressor of c-Myc induced B cell leukemia.
    Pathak S; Ma S; Trinh L; Eudy J; Wagner KU; Joshi SS; Lu R
    PLoS One; 2011; 6(7):e22628. PubMed ID: 21818355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
    Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
    Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
    Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
    [TBL] [Abstract][Full Text] [Related]  

    Licht JD
    Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
    Bolomsky A; Ceribelli M; Scheich S; Rinaldi K; Huang DW; Chakraborty P; Pham L; Wright GW; Hsiao T; Morris V; Choi J; Phelan JD; Holewinski RJ; Andresson T; Wisniewski J; Riley D; Pittaluga S; Hill E; Thomas CJ; Muppidi J; Young RM
    Cancer Cell; 2024 Jul; 42(7):1185-1201.e14. PubMed ID: 38906156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 Jul; 30(14):3023-3035. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma.
    Conery AR; Centore RC; Neiss A; Keller PJ; Joshi S; Spillane KL; Sandy P; Hatton C; Pardo E; Zawadzke L; Bommi-Reddy A; Gascoigne KE; Bryant BM; Mertz JA; Sims RJ
    Elife; 2016 Jan; 5():. PubMed ID: 26731516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.
    Lee HR; Doğanay S; Chung B; Toth Z; Brulois K; Lee S; Kanketayeva Z; Feng P; Ha T; Jung JU
    J Virol; 2014 Feb; 88(4):2183-94. PubMed ID: 24335298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimony enhances c-Myc stability in prostate cancer via activating CtBP2-ROCK1 signaling pathway.
    Zhang C; Lu C; Wang Z; Feng G; Du E; Liu Y; Wang L; Qiao B; Xu Y; Zhang Z
    Ecotoxicol Environ Saf; 2018 Nov; 164():61-68. PubMed ID: 30098506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
    Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
    J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
    Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.